Contineum Therapeutics (NASDAQ:CTNM) Sees Strong Trading Volume

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) saw an uptick in trading volume on Tuesday . 62,821 shares traded hands during mid-day trading, a decline of 33% from the previous session’s volume of 94,401 shares.The stock last traded at $20.88 and had previously closed at $21.00.

Analysts Set New Price Targets

Several research firms have recently issued reports on CTNM. Stifel Nicolaus began coverage on shares of Contineum Therapeutics in a research note on Tuesday, April 30th. They issued a “buy” rating and a $29.00 target price for the company. Morgan Stanley initiated coverage on shares of Contineum Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $25.00 target price for the company. Finally, Royal Bank of Canada initiated coverage on shares of Contineum Therapeutics in a report on Tuesday, April 30th. They issued an “outperform” rating and a $30.00 price target on the stock.

Contineum Therapeutics Trading Down 2.9 %

The company has a fifty day moving average price of $16.61.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Thursday, May 16th. The company reported ($3.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($3.02). On average, analysts anticipate that Contineum Therapeutics, Inc. will post -1.95 EPS for the current year.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).